Bio-Techne (NASDAQ: TECH) reported Q2 EPS of $1.88, $0.09 better than the analyst estimate of $1.79. Revenue for the quarter came in at $269.3 million versus the consensus estimate of $266.57 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.